RU2015105561A - SUBSTITUTED HETEROAZEPINONES - Google Patents
SUBSTITUTED HETEROAZEPINONES Download PDFInfo
- Publication number
- RU2015105561A RU2015105561A RU2015105561A RU2015105561A RU2015105561A RU 2015105561 A RU2015105561 A RU 2015105561A RU 2015105561 A RU2015105561 A RU 2015105561A RU 2015105561 A RU2015105561 A RU 2015105561A RU 2015105561 A RU2015105561 A RU 2015105561A
- Authority
- RU
- Russia
- Prior art keywords
- alkyl
- methyl
- oxo
- aryl
- methylamino
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D267/02—Seven-membered rings
- C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D267/14—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D267/02—Seven-membered rings
- C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D281/02—Seven-membered rings
- C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D281/10—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
1. Соединение формулыв которомW и X одинаковы или различны и независимо выбраны из Н, С-алкила, гидрокси-С-алкила, арил-С-алкила, С-циклоалкил-С-алкила, С-алкенил-С-алкила, С-алкинил-С-алкила и гетероцикла илиX и W совместно с атомом азота, к которому они присоединены, могут образовывать С-гетероцикл, или W совместно с атомом азота, к которому он присоединен, и Y совместно с атомом углерода, к которому он присоединен, могут образовывать С-гетероцикл;Y представляет собой d-6-алкил, гидрокси-С-алкил или С-циклоалкил-С-алкил;R1 выбран из Н, галогена, C-алкила, галоген-С-алкила, арил-С-алкила, С-циклоалкил-С-алкила, СООН, C(O)NR8′R9′, ацила, OR7, SR7, NR8R9, N-ацила, N-сульфонила, цианогруппы и SOR10;Rвыбран из Н, галогена, C-алкила, арил-С-алкила, С-циклоалкил-C-алкила, ацила, OR7, SR7, NR8R9, N-ацила, N-сульфонила, цианогруппы и SOR10;R3 выбран из Н, галогена, C-алкила, галоген-С-алкила, арил-С-алкила, С-циклоалкил-С-алкила, ацила, OR7, SR7, NR8R9, N-ацила, N-сульфонила, цианогруппы и SOR10;R4 представляет собой Н или C-алкил;R5 и R6 одинаковы или различны и независимо выбраны из Н, С-алкила, С-алкил-S-С-алкила, С-алкил-О-С-алкила, арила и С-циклоалкила илиR5 и R6 совместно с атомом углерода, к которому они присоединены, могут образовывать С-карбоцикл или гетероцикл, который, возможно, замещен группой C-алкил-SO;V представляет собой S, О или SO,Z выбран из C-алкила,арила, возможно замещенного С-циклоалкилом, C-алкилом, C-алкоксигруппой, галогеном, галоген-С-алкоксигруппой, С(O)N(С-алкил,С-алкил), C(O)NHSO-C-алкилом, С(O)N(С-алкил,гидрокси-С-алкил), С(O)N(С-алкил,СООН-С-алкил), фенилом, возможно замещенным цианогруппой, COO-C-алкилом или СООН; арил-С-алкила,гетероарила, возможно замещенного цианогруппой, C-алкоксигруппой или фенилом, возможно замещенным группой С(O)N(Н,С-алкил), цианогруппой или COOH,полициклических ароматических1. A compound of the formula wherein W and X are the same or different and independently selected from H, C-alkyl, hydroxy-C-alkyl, aryl-C-alkyl, C-cycloalkyl-C-alkyl, C-alkenyl-C-alkyl, C- alkynyl-C-alkyl and heterocycle or X and W together with the nitrogen atom to which they are attached can form a C-heterocycle, or W together with the nitrogen atom to which it is attached, and Y together with the carbon atom to which it is attached, can form a C-heterocycle; Y represents d-6-alkyl, hydroxy-C-alkyl or C-cycloalkyl-C-alkyl; R1 is selected from H, halogen, C-alkyl, halogen-C-alkyl, aryl-C-alkyl, C-cycloalkyl-C-alkyl, COOH, C (O) NR8′R9 ′, acyl, OR7, SR7, NR8R9, N-acyl, N-sulfonyl, cyano and SOR10 ; R is selected from H, halogen, C-alkyl, aryl-C-alkyl, C-cycloalkyl-C-alkyl, acyl, OR7, SR7, NR8R9, N-acyl, N-sulfonyl, cyano and SOR10; R3 is selected from H, halogen, C-alkyl, halogen-C-alkyl, aryl-C-alkyl, C-cycloalkyl-C-alkyl, acyl, OR7, SR7, NR8R9, N-acyl, N-sulfonyl, cyano and SOR10; R4 represents H or C-alkyl; R5 and R6 are the same or different and are independently selected from H, C-alkyl, C-alkyl-S-C-alkyl, C-alkyl-O-C-alkyl, aryl and C-cycloalkyl or R5 and R6, together with the carbon atom to which they are attached, can form a C-carbocycle or heterocycle which is optionally substituted with a C-alkyl-SO group; V is S, O or SO, Z is selected from C-alkyl, aryl, optionally substituted with C-cycloalkyl, C-alkyl, C-alkoxy, halogen, halogen-C-alkoxy, C (O) N (C-alkyl, C-alkyl), C (O) NHSO-C-alkyl, C (O ) N (C-alkyl, hydroxy-C-alkyl), C (O) N (C-alkyl, COOH-C-alkyl), phenyl optionally substituted with cyano, COO-C-alkyl or COOH; aryl-C-alkyl, heteroaryl, optionally substituted with cyano, C-alkoxy, or phenyl, optionally substituted with C (O) N (H, C-alkyl), cyano or COOH, polycyclic aromatic
Claims (26)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261681337P | 2012-08-09 | 2012-08-09 | |
US61/681,337 | 2012-08-09 | ||
PCT/EP2013/066431 WO2014023708A1 (en) | 2012-08-09 | 2013-08-06 | Substituted hetero-azepinones |
Publications (1)
Publication Number | Publication Date |
---|---|
RU2015105561A true RU2015105561A (en) | 2016-09-27 |
Family
ID=48951449
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2015105561A RU2015105561A (en) | 2012-08-09 | 2013-08-06 | SUBSTITUTED HETEROAZEPINONES |
Country Status (11)
Country | Link |
---|---|
US (1) | US9394263B2 (en) |
EP (1) | EP2882725A1 (en) |
JP (1) | JP6266617B2 (en) |
KR (1) | KR20150041647A (en) |
CN (1) | CN104470905B (en) |
BR (1) | BR112015001830A2 (en) |
CA (1) | CA2877048A1 (en) |
HK (1) | HK1206740A1 (en) |
MX (1) | MX2015001720A (en) |
RU (1) | RU2015105561A (en) |
WO (1) | WO2014023708A1 (en) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112015004547A8 (en) * | 2012-09-19 | 2018-01-23 | Hoffmann La Roche | compounds, pharmaceutical composition, use of a compound and method for treating or ameliorating cancer |
WO2016079527A1 (en) | 2014-11-19 | 2016-05-26 | Tetralogic Birinapant Uk Ltd | Combination therapy |
WO2016097773A1 (en) | 2014-12-19 | 2016-06-23 | Children's Cancer Institute | Therapeutic iap antagonists for treating proliferative disorders |
WO2017004500A1 (en) | 2015-07-02 | 2017-01-05 | Genentech, Inc. | Bicyclic lactams and methods of use thereof |
CN106467521A (en) * | 2015-08-14 | 2017-03-01 | 陈志龙 | Two kinds of preparation methoies of one class bisbenzimidazole indole derivativeses |
CN106467515B (en) * | 2015-08-18 | 2019-09-24 | 宁波洞密生物科技有限公司 | Application of a kind of 6- pyridine benzimidazole indole derivatives and preparation method thereof with field of medicaments |
WO2017136727A2 (en) | 2016-02-05 | 2017-08-10 | Denali Therapeutics Inc. | Compounds, compositions and methods |
JP7349359B2 (en) | 2016-10-17 | 2023-09-22 | エフ. ホフマン-ラ ロシュ アーゲー | Bicyclic pyridone lactams and methods of using them. |
JP7208137B2 (en) | 2016-12-09 | 2023-01-18 | デナリ セラピューティクス インコーポレイテッド | Compounds, compositions and methods |
US11072607B2 (en) | 2016-12-16 | 2021-07-27 | Genentech, Inc. | Inhibitors of RIP1 kinase and methods of use thereof |
WO2019204537A1 (en) | 2018-04-20 | 2019-10-24 | Genentech, Inc. | N-[4-oxo-2,3-dihydro-1,5-benzoxazepin-3-yl]-5,6-dihydro-4h-pyrrolo[1,2-b]pyrazol e-2-carboxamide derivatives and related compounds as rip1 kinase inhibitors for treating e.g. irritable bowel syndrome (ibs) |
EP3831811A4 (en) | 2018-07-31 | 2022-04-20 | Fimecs, Inc. | Heterocyclic compound |
WO2021020585A1 (en) | 2019-07-31 | 2021-02-04 | ファイメクス株式会社 | Heterocyclic compound |
CR20230382A (en) * | 2021-02-12 | 2023-09-06 | Hoffmann La Roche | Bicyclic tetrahydroazepine derivatives for the treatment of cancer |
WO2023030295A1 (en) * | 2021-09-01 | 2023-03-09 | 先声再明医药有限公司 | Ubiquitin specific protease 1 (usp1) inhibitor |
TW202334164A (en) | 2022-01-12 | 2023-09-01 | 美商戴納立製藥公司 | Crystalline forms of (s)-5-benzyl-n-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido [3,2-b][1,4]oxazepin-3-yl)-4h-1,2,4-triazole-3-carboxamide |
WO2023150790A2 (en) * | 2022-02-07 | 2023-08-10 | The Wistar Institute Of Anatomy And Biology | Novel and highly selective sars-cov-2 mpro inhibitors |
WO2024033389A1 (en) * | 2022-08-11 | 2024-02-15 | F. Hoffmann-La Roche Ag | Bicyclic tetrahydrothiazepine derivatives |
WO2024033457A1 (en) * | 2022-08-11 | 2024-02-15 | F. Hoffmann-La Roche Ag | Bicyclic tetrahydrothiazepine derivatives |
WO2024033458A1 (en) * | 2022-08-11 | 2024-02-15 | F. Hoffmann-La Roche Ag | Bicyclic tetrahydroazepine derivatives |
WO2024033388A1 (en) * | 2022-08-11 | 2024-02-15 | F. Hoffmann-La Roche Ag | Bicyclic tetrahydrothiazepine derivatives |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9420763D0 (en) | 1994-10-14 | 1994-11-30 | Glaxo Inc | Acetamide derivatives |
TW200502221A (en) * | 2002-10-03 | 2005-01-16 | Astrazeneca Ab | Novel lactams and uses thereof |
WO2006065218A1 (en) * | 2004-12-14 | 2006-06-22 | Astrazeneca Ab | Novel molecular probes |
MX2007015419A (en) | 2005-06-08 | 2008-02-21 | Novartis Ag | Organic compounds. |
WO2007101347A1 (en) * | 2006-03-07 | 2007-09-13 | Aegera Therapeutics Inc. | Bir domain binding compounds |
JP2009529518A (en) * | 2006-03-10 | 2009-08-20 | アストラゼネカ アクチボラグ | Compound |
WO2008106077A1 (en) * | 2007-02-28 | 2008-09-04 | Merck & Co., Inc. | Substituted benzodiazepinones, benzoxazepinones and benzothiazepinones as sodium channel blockers |
-
2013
- 2013-08-06 RU RU2015105561A patent/RU2015105561A/en not_active Application Discontinuation
- 2013-08-06 EP EP13747659.4A patent/EP2882725A1/en not_active Withdrawn
- 2013-08-06 MX MX2015001720A patent/MX2015001720A/en unknown
- 2013-08-06 JP JP2015525858A patent/JP6266617B2/en not_active Expired - Fee Related
- 2013-08-06 CA CA2877048A patent/CA2877048A1/en not_active Abandoned
- 2013-08-06 KR KR20157005929A patent/KR20150041647A/en not_active Application Discontinuation
- 2013-08-06 BR BR112015001830A patent/BR112015001830A2/en not_active IP Right Cessation
- 2013-08-06 CN CN201380035993.XA patent/CN104470905B/en not_active Expired - Fee Related
- 2013-08-06 WO PCT/EP2013/066431 patent/WO2014023708A1/en active Application Filing
- 2013-08-06 US US14/418,383 patent/US9394263B2/en not_active Expired - Fee Related
-
2015
- 2015-07-31 HK HK15107346.9A patent/HK1206740A1/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
EP2882725A1 (en) | 2015-06-17 |
BR112015001830A2 (en) | 2017-07-04 |
KR20150041647A (en) | 2015-04-16 |
CA2877048A1 (en) | 2014-02-13 |
US20150361059A1 (en) | 2015-12-17 |
US9394263B2 (en) | 2016-07-19 |
MX2015001720A (en) | 2015-04-14 |
CN104470905A (en) | 2015-03-25 |
JP2015528821A (en) | 2015-10-01 |
WO2014023708A1 (en) | 2014-02-13 |
JP6266617B2 (en) | 2018-01-24 |
HK1206740A1 (en) | 2016-01-15 |
CN104470905B (en) | 2017-09-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2015105561A (en) | SUBSTITUTED HETEROAZEPINONES | |
JP2015528821A5 (en) | ||
CY1120179T1 (en) | HYDROCYCLIC COMPOUND CONTAINING NITROGEN OR SALT THIS | |
ES2675022T3 (en) | Indolamine 2,3-dioxygenase inhibitors (IDO) | |
PE20230161A1 (en) | INHIBITORS OF MUTANT KRAS PROTEINS | |
JP2013538801A5 (en) | ||
ES2617619T3 (en) | Drug combinations comprising a DGAT inhibitor and a PPAR agonist | |
RU2373209C2 (en) | Pyrrolotriazine compounds as kinase inhibitors | |
EA200601287A1 (en) | DERIVATIVES (3-OXO-3,4-DIHYDROCHINOXALIN-2-ILAMINO) BENZAMIDE AND RELATED COMPOUNDS AS GLYCOGEN PHOSPHORILASE INHIBITORS FOR TREATING DIABETES AND OBSERVATION | |
PE20050020A1 (en) | DERIVATIVES 4- (2-OXO-2,3-DIHYDRO-1-H-IMIDAZO [4,5-b] PYRIDIN-1-IL) -N- (2-OXO-AZEPAN-3-IL) PIPERIDINIL-1- CARBOXAMIDE SUBSTITUTED AS CGRP RECEPTOR ANTAGONISTS | |
PE20061156A1 (en) | BENZAMIDE DERIVATIVES AS INHIBITING AGENTS OF THE GLYCINE TRANSPORTER | |
PE20151249A1 (en) | PYRAZOLOPYRIMIDINE DERIVATIVES AS INHIBITORS OF JAK KINASES | |
PE20142216A1 (en) | INDAZOLE INHIBITORS FROM THE WNT SIGNALING ROUTE AND THERAPEUTIC USES OF THE SAME | |
TW200745029A (en) | Sulfonamide derivatives exhibiting PGD2 receptor antagonism | |
TW200800938A (en) | Indole carboxylic acid derivatives exhibiting PGD2 receptor antagonism | |
PE20141700A1 (en) | 2- (2,4,5-ANILINE SUBSTITUTED) PYRIMIDINE COMPOUNDS | |
JP2012520867A5 (en) | ||
JP2015503507A5 (en) | ||
PE20121352A1 (en) | HETEROARYL DERIVATIVES CONTAINING N AS INHIBITORS OF KINASE JAK3 | |
RU2015112192A (en) | 2-OXO-2,3,4,5-TETRAHYDRO-1H-BENZO [B] DIAZEPINE AND THEIR APPLICATION FOR TREATMENT OF CANCER | |
PE20140934A1 (en) | DERIVATIVES OF PIRAZOLE | |
PE20051095A1 (en) | 1H-HAVE [2,3-c] PIRAZOLE DERIVATIVES USEFUL AS KINASE INHIBITORS | |
PE20100737A1 (en) | NEW COMPOUNDS | |
PE20140966A1 (en) | QUINAZOLINE CARBOXAMIDE AZETHYDINES | |
PE20081351A1 (en) | QUINAZOLINE DERIVATIVES AS ANTI-CANCER AGENTS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20171025 |